Melphalan: A Promising Agent in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
- 26 November 2013
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 21 (3) , 908-914
Abstract
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has become an option for peritoneal carcinomatosis (PC). Frequently, these patients have failed systemic chemotherapies and surgeries, including CRS/HIPEC with traditional regimens (mitomycin-C or platinum based). An alternative agent for failed or repeated CRS/HIPEC is unknown. We hypothesize that melphalan is an alternative agent in patients with PC from aggressive primaries, including recurrences following failed regional therapies. A retrospective review of a prospective database of 247 patients revealed 25 patients (9 male and 16 female) who received intraperitoneal melphalan (50 mg/m2) in 31 CRS/HIPEC procedures, of which 19 were repeated. Primary malignancies included 17 appendiceal, one colorectal, two ovarian, two uterine sarcomas, two primary peritoneal and one mesentery sarcoma. PC index (PCI) was ≥20 in 76 % of patients (19/25). 88 % of patients (22/25) had complete cytoreduction. Seventeen patients were alive, with mean survival of 63.6 months, and eight patients are deceased. Overall survival (OS) for the entire group since diagnosis was 95.8, 84.5, 50.9, and 38.2 % at 1, 3, 5, and 10 years, respectively; OS since melphalan HIPEC was 89.4, 45, and 30 % at 1, 3, and 5 years, respectively; and OS in patients with appendiceal malignancies was 91.7, 48.1 and 32.1 % at 1, 3 and 5 years, respectively. There was no postoperative mortality. Grade III–IV morbidity was 23 % (7/31). Nine patents had neutropenia, controlled with filgrastim. Melphalan is an efficacious alternative agent in patients undergoing CRS/HIPEC for aggressive and recurrent peritoneal surface malignancies. Its postoperative significant myelosuppression effect should be addressed.Keywords
This publication has 37 references indexed in Scilit:
- Melphalan exposure induces an interleukin-6 deficit in bone marrow stromal cells and osteoblastsCytokine, 2012
- Treatment of Colorectal Peritoneal Carcinomatosis With Systemic Chemotherapy: A Pooled Analysis of North Central Cancer Treatment Group Phase III Trials N9741 and N9841Journal of Clinical Oncology, 2012
- Local and intralesional therapy of in‐transit melanoma metastasesJournal of Surgical Oncology, 2011
- Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225 Regional Chemotherapy Treatments between 1995 and 2010 at a Single InstitutionJournal of the American College of Surgeons, 2011
- Prognostic Significance of Lymph Node Metastases in Patients with High-Grade Appendiceal CancerAnnals of Surgical Oncology, 2011
- The Role of Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CRS/HIPEC) in Patients with High-Grade Appendiceal Carcinoma and Extensive Peritoneal CarcinomatosisAnnals of Surgical Oncology, 2011
- Epithelial Appendiceal NeoplasmsThe Cancer Journal, 2009
- Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non‐appendiceal peritoneal carcinomatosis from a prospective databaseJournal of Surgical Oncology, 2007
- Thermal enhancement of melphalan and oxaliplatin cytotoxicity in vitroInternational Journal of Hyperthermia, 2002
- Outcome of Palliative Operations for Malignant Bowel Obstruction in Patients With Peritoneal Carcinomatosis From Nongynecological CancerAnnals of Surgical Oncology, 2001